Simple route to ferrocenylalkyl nucleobases. Antitumor activity  in vivo | Zendy

Simenel Alexander A. | Zendy; Morozova Elena A. | Zendy; Snegur Lubov' V. | Zendy; Zykova Svetlana I. | Zendy; Kachala Vadim V. | Zendy; Ostrovskaya Larissa A. | Zendy; Bluchterova Natalia V. | Zendy; Fomina Margarita M. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Simple route to ferrocenylalkyl nucleobases. Antitumor activity in vivo

Author(s) -

Simenel Alexander A.,

Morozova Elena A.,

Snegur Lubov' V.,

Zykova Svetlana I.,

Kachala Vadim V.,

Ostrovskaya Larissa A.,

Bluchterova Natalia V.,

Fomina Margarita M.

Publication year - 2009

Publication title -

applied organometallic chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.53

H-Index - 71

eISSN - 1099-0739

pISSN - 0268-2605

DOI - 10.1002/aoc.1500

Subject(s) - chemistry , lewis lung carcinoma , nucleobase , thymine , cytosine , in vivo , stereochemistry , uracil , combinatorial chemistry , dna , biochemistry , cancer , medicine , microbiology and biotechnology , biology , metastasis

Ferrocenylalkyl nucleobases ( 1 – 14 ) were prepared via the reaction of the α‐(hydroxy)alkyl ferrocenes FcCHR(OH) (Fc = ferrocenyl; R = H, Me, Et, Ph) with thymine, cytosine, iodo‐cytosine and adenine in DMSO at 100 °C, yields being 50–80%. The antitumor activities of ferrocenylmethyl thymine ( 1 ) against solid tumor models, carcinoma 755 (Ca755) and Lewis lung carcinoma (LLC) were studied in vivo . Therapeutic synergism of antitumor activity against LLC was demonstrated in the case of combined application of compound 1 with anticancer drug cyclophosphamide. Copyright © 2009 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research